Zobrazeno 1 - 10
of 25
pro vyhledávání: '"Eun Mi Yu"'
Publikováno v:
Exploration of Targeted Anti-tumor Therapy, Vol 5, Iss 4, Pp 971-980 (2024)
The landscape of treatment for first-line therapy in advanced urothelial cancer (aUC) and metastatic urothelial cancer (mUC) has rapidly changed in the last year alone. Maintenance avelumab remains a viable treatment option for many patients across t
Externí odkaz:
https://doaj.org/article/ee912ee85e4a450a8dbcfa0f46fee688
Publikováno v:
Uro, Vol 3, Iss 2, Pp 117-131 (2023)
Approximately a third of patients diagnosed with kidney cancer in the United States present with advanced disease and those who present with distant metastases historically had dismal 5-year relative survival. However, over the last several years, ad
Externí odkaz:
https://doaj.org/article/310e1028ccac405dbbac207fef575e58
Publikováno v:
Therapeutic Advances in Urology, Vol 15 (2023)
Maintenance therapy with immune checkpoint inhibitors (ICIs) has changed the treatment paradigm of metastatic urothelial carcinoma (mUC). The JAVELIN Bladder 100 trial established avelumab, one of several ICIs in use today, as a life-prolonging maint
Externí odkaz:
https://doaj.org/article/c66434ef54354f5191dcc85a3254ee22
Publikováno v:
Cancer Treatment and Research Communications, Vol 33, Iss , Pp 100661- (2022)
Non-urothelial bladder cancers make up a rare minority of all genitourinary (GU) tract histologic cancers since urothelial cancer (UC) makes up the most common histologic subtype. Bladder cancer variant histology (BCVH) or urothelial variants also oc
Externí odkaz:
https://doaj.org/article/0da72710689647aa83d90d584d383e56
Publikováno v:
Vaccines, Vol 9, Iss 8, p 919 (2021)
The use of checkpoint inhibitors in advanced and metastatic renal cell carcinomas (RCCs) has rapidly evolved over the past several years. While immune-oncology (IO) drug therapy has been successful at resulting in improved responses and survival, com
Externí odkaz:
https://doaj.org/article/275ac4d4054c481097ae88e2bdf13b9b
Autor:
Yong-Hae Jung, Eun-Mi Yu
Publikováno v:
Journal of Korean Society Of Exhibition Design Studies. 36:63-70
Autor:
Eun-mi Yu, Jeanny B. Aragon-Ching
Publikováno v:
Expert opinion on pharmacotherapy. 23(9)
Androgen deprivation therapy (ADT) has been a treatment of choice for prostate cancer in almost all phases, particularly in the locally advanced, metastatic setting in both hormone-sensitive and castration-resistant diseaseand in those who are unfit
Autor:
Eun-Mi Yu, Yong-Hae Jung
Publikováno v:
Journal of Korean Society Of Exhibition Design Studies. 16:57-68
Publikováno v:
Vaccines, Vol 9, Iss 919, p 919 (2021)
Vaccines
Vaccines
The use of checkpoint inhibitors in advanced and metastatic renal cell carcinomas (RCCs) has rapidly evolved over the past several years. While immune-oncology (IO) drug therapy has been successful at resulting in improved responses and survival, com
Autor:
Young Ho Kim, Rohit Singh, Seon Hee Kim, Beom K. Choi, Eun Mi Yu, Eunjung Cho, Seongeun Han, Don G. Lee, Chungyong Han, Byoung S. Kwon
Publikováno v:
Cells, Vol 10, Iss 2018, p 2018 (2021)
Cells
Volume 10
Issue 8
Cells
Volume 10
Issue 8
Adoptive cell therapy (ACT) using tumor-reactive T cells is a promising form of immunotherapy to specifically target cancer. However, the survival and functional maintenance of adoptively transferred T cells remains a challenge, ultimately limiting t